Conference Proceedings

A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM).

Paul G Richardson, Michel Attal, S Vincent Rajkumar, Jesus San Miguel, Meral Beksac, Ivan Spicka, Xavier Leleu, Fredrik Schjesvold, Philippe Moreau, Meletios A Dimopoulos, Jeffrey SY Huang, Jiri Minarik, Michele Cavo, H Miles Prince, Sandrine Mace, Kathryn Penkus Corzo, Frank Campana, Solenn Le-Guennec, Franck Dubin, Kenneth Carl Anderson

JOURNAL OF CLINICAL ONCOLOGY | AMER SOC CLINICAL ONCOLOGY | Published : 2019